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Abstract 
Background 
Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with 
selective subtypes of advanced soft-tissue sarcoma (STS) who have previously received standard 
chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The 
main objective of this study was to investigate the activity of pazopanib in vascular sarcomas. 
Patients and methods 
A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), 
epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life 
practice at  EORTC centers as well as patients treated within the EORTC Phase II and III clinical trials 
(62043/62072) was performed. Patient and tumor characteristics were collected. Response was 
assessed according to RECIST 1.1. and survival analysis was performed.  
Results 
Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and 2 (3.8%) with AS, HE and IS, 
respectively. The response rate was 8 (20%), 2 (20%) and 2 (100%) in the AS, HE and IS subtypes, 
respectively. There was no difference in response rate between cutaneous and non-cutaneous AS 
and similarly between radiation-associated and non-radiation-associated AS. Median PFS and median 
OS (from commencing pazopanib) were 3 months (95% Cl: 2.1-4.4) and 9.9 months (95% Cl: 6.5-
11.3) in AS, respectively. 
Conclusion 
The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this 
study, the activity of pazopanib was similar in cutaneous/ non-cutaneous and in radiation/ non-
radiation associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of 
further evaluation.  
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Introduction 
Soft tissue sarcomas (STS) represent a highly heterogeneous group of tumors with differing 
underlying biology, clinical behavior and response to systemic therapy.(1) Within this family of tumors, 
vascular sarcomas such as angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal 
sarcoma (IS), account for about 2-3% of adult STS.(2) The worldwide age-standardized incidence rate 
of angiosarcoma is approximately 0.1/ 100000/year.(3) 
There are few prospective data on the utility of systemic therapy in vascular sarcomas.  The majority 
of prospective trials evaluating systemic therapies in sarcomas, have generally included all or many 
STS subtypes in a one size fits all approach. Consequently, the number of patients with vascular 
sarcomas in such trials is low. Based on retrospective data, standard first and second line therapy for 
angiosarcoma include doxorubicin- and taxane-based regimens. Furthermore, there have been a 
number of phase II trials in angiosarcoma. The phase II AngioTax trial reported a response rate to 
weekly paclitaxel of 20% with a disease stabilization rate of 75% after 3 months and 24% after 6 
months.(4) First-line single-agent doxorubicin and weekly paclitaxel seem to have similar efficacy in 
metastatic AS.(5, 6) First-line anthracycline-based chemotherapy was associated with a partial 
response rate of 25% and a median progression-free survival (PFS) of 4.9 months.(7) 
Vascular sarcomas are known to express pro-angiogenic growth factors such as vascular endothelial 
growth factor (VEGF).(8) Therefore, the evaluation of vascular-targeted agents in vascular tumors 
such as AS, HE and IS is of particular interest. Accordingly, bevacizumab was investigated for the 
treatment of AS and HE confirming promising efficacy results represented by a median PFS of 12 and 
52.7 weeks, respectively.(9) In two Phase II trials by Maki and Ray-Coquard and colleagues a median 
PFS in the range of 1.8 - 3.8 months, respectively, was reported for for sorafenib in AS.(10, 11) 
Pazopanib is a tyrosine kinase inhibitor targeting several factors including VEGFR1-3 and PDGFR and 
has been approved  by the European Medicines Agency (EMA) for the treatment of patients with 
advanced non-adipocytic STS who have previously been treated with anthracycline- or ifosfamide-
based chemotherapy.(12) There are few published data on the efficacy of pazopanib in vascular 
sarcomas.(13) Due to the small number of patients with vascular sarcomas included in the EORTC 
soft tissue sarcoma Phase II and III trials, a meaningful evaluation of its activity in these subtypes is 
not possible .(14, 15) There have been case reports and small case series documenting the potential 
efficacy of pazopanib in vascular sarcomas.(16-19) In addition, pazopanib is the only tyrosine kinase 
inhibitor approved for non-adipocytic STS together with imatinib in DFSP, and therefore further 
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evaluation of this agent in vascular sarcomas has an added value. Consequently, the aim of this study 
was to document the efficacy and safety of pazopanib in a cohort of patients with advanced vascular 
sarcomas treated at a number of EORTC centers and within the two EORTC trials, in order to provide 
a benchmark for further studies and clinical practice.  
 
Material and Methods 
Patient population and data collection 
Ethical approval was obtained according to local and national regulations. A retrospective search of 
patients with advanced vascular sarcomas treated with pazopanib at EORTC STBSG centers was 
performed. In addition, patients with vascular sarcomas treated within the Phase II and III EORTC 
pazopanib trials  (62043/62072) were identified. Patients were included in the analysis regardless of 
treatment line. In some patients pazopanib was given in the first-line setting as pazopanib is 
reimbursed in several countries as first-line therapy if patients are not suitable for treatment with 
anthracyclines. and pPazopanib was administered according to standard ESMO Guidelines and local 
institutional policy. Clinical, pathological and outcome data were obtained from the individual patient 
records and from the EORTC database for the patients treated within trials.  The diagnosis was 
confirmed in all cases by an experienced STS pathologist. All patients (but one) were confirmed to 
have progressive disease before treatment start.   
 
Endpoints 
The study endpoints were response rate to pazopanib, progression free survival (PFS) and overall 
survival (OS). The objective response rate was assessed per RECIST 1.1. The disease control rate 
was defined as the sum of complete response, partial response and stable disease. PFS was defined 
from the date of commencing pazopanib to the first documentation of progression or death. For data 
obtained  from the EORTC trials, the definition of progression was according to the radiological 
assessment of the principal investigator; in the absence of radiologically documented progression, 
clinical progression was also taken into account.  
OS was calculated from the starting date of pazopanib administration to the date of death. Patients 
alive at the time of analysis were censored at the date of last follow-up.  For patients with 
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angiosarcoma treated with pazopanib, the outcome of those with cutaneous and non-cutaneous types 
was compared, and likewise for radiation-associated and non-radiation-associated. 
 
Statistical analysis 
Descriptive summary statistics of patients, tumor and treatment characteristics, and response to 
treatment are provided overall as well as stratified by the histologic subtypes of vascular sarcoma (AS, 
HE and IS). Furthermore, the response rate of AS was determined by origin of the primary tumor 
(cutaneous/ non-cutaneous) and by association with radiation therapy (Yes, No), and tested for 
association with these covariates using a Chi-square test. 
Survival curves for PFS and OS were generated using the Kaplan-Meier method for the different 
histologic subtypes. Estimates of medians and corresponding 95% confidence intervals (CI) are 
reported. 
 
Results 
Patient and tumor characteristics 
A total of 52 patients were identified, including 9 patients from the EORTC Phase II and III trials 
(62043 and 62072). Sixteen institutions in eight countries contributed to this analysis. Baseline 
patients and tumor characteristics are summarized in Table 1. Among the vascular sarcoma patients 
included, 40 (76.9%) had AS, ten (19.2%) had HE and two (3.8%) had IS. Focusing on the AS cohort 
the overall median age at diagnosis was 62.4 years (range: 30- 83.4yrs). 62.5% of patients were male. 
The most common primary tumor site was breast (n=15) and scalp (n=6). Additionally, AS was 
diagnosed in the abdomen (adrenal gland, liver, genitourinary) (n=8), chest (including pulmonary 
artery) (n=7) and extremities (n=4). Twenty-four patients (60%) had non-cutaneous angiosarcoma and 
14 patients (35%) had radiation-associated angiosarcoma.  
 
Treatment details before and after pazopanib 
In five patients (9.6%) pazopanib was given in the first-line setting (Table 4). The most commonly 
administered previous treatments were paclitaxel (54.5%, n=25) and doxorubicin (43.5%, n=20). The 
details of other treatments administered are displayed in table 5 (see Appendix). 
Of the patients on follow-up at the time of analysis, 21 (48.8%) received no additional therapy, 18 
(41.9%) received one further line of therapy and 4 patients (9.3%) received two further lines of therapy 
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(Table 4). The most commonly administered drugs following progressive disease on pazopanib were 
gemcitabine (21.1%, n=8) and paclitaxel (18.4%, n=7). Details for the other therapies administered are 
provided in table 65 (see Appendix). 
 
Clinical outcome and prognostic factors 
All patients (but one) were confirmed to have progressive disease before treatment start.  The median 
follow-up was 15.9 months (95%CI: 12.8 - 38.2), and it was not possible to obtain response data for 3 
patients (5.8%). Overall, 26 patients (50%) experienced progressive disease, eleven patients (21.2%) 
had stable disease, eleven patients (21.2%) a partial response and one patient (1.9%) had a complete 
response (Table 2), leading to a disease control rate for the total group of 44.3%. 
In the AS cohort, the rate of partial response and stable disease was 20% and 17.5%, respectively, 
representing a clinical benefit rate of 37.5% (Table 2). The response rate was similar in cutaneous and 
non-cutaneous AS, 26.7% and 24.2% (p= 0.86), respectively. Furthermore, the response rate was 
26.7% in the radiation-associated AS cohort and 23.5% in the non-radiation-associated AS cohort 
(p=0.81), respectively (Table 3). 
In the cohort of patients with HE, the clinical benefit rate was 60% of which 67% (i.e. 4 out of 6) 
experienced disease stabilization as the best response. Of note, both patients with IS had a partial 
response (Table 2). 
The median PFS was 3 months (95% Cl: 2.1-4.4) in the AS cohort and 26.3 months (0.2-N) in the HE 
cohort, respectively (Figures 1 and 2). The median OS from date of treatment start was 9.9 months 
(95% Cl: 6.5-11.3) and 26.3 months (95% Cl: 0.5-N) for AS and HE, respectively.  
 
 
Discussion 
STS represent a group of rare and heterogeneous tumors of mesenchymal origin, with each subtype 
having differing underlying biology, clinical behavior and response to systemic therapy. In view of the 
rarity of these tumors they have often been grouped together for the purpose of clinical trials, and 
consequently the results of such trials have often been difficult to interpret with regard to the benefit of 
an individual drug or schedule in a specific subtype. We aimed to get more information on a couple of 
vascular sarcomas in patients treated with pazopanib within the first clinical trials and in daily clinical 
practice after registration. 
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Our study documented a disease control rate of 40% and a median PFS of 3 months for AS patients 
treated with pazopanib. These results are consistent with the phase II data of sorafenib in AS.(10) In 
the PALETTE trial, the median PFS of 4.6 months was slightly higher in the STS group overall.(15)  
Up-regulation of angiogenic growth factors is thought to play a major role in  the pathomechanism of 
several tumors, including angiosarcomas. In the latter Itakura et al. report on an immunohistochemical 
expression of certain VEGFs and their receptors in over 90% of patients.(20) Therefore, one would 
expect a higher response rate to angiogenic drugs in AS patients when compared to other STS. 
However, our results do not support this assumption. It should be noted that the patients in our cohort 
were heavily pretreated with 25% having received more than two lines of systemic therapy prior to 
commencing pazopanib. The most commonly employed chemotherapy drugs were paclitaxel, 
gemcitabine and liposomal doxorubicin. 
Several retrospective studies suggest that cutaneous angiosarcoma is a relatively chemosensitive 
subtype, particularly to paclitaxel, but data on targeted agents are lacking.(21) However, in our cohort 
no difference in the efficacy of pazopanib was observed between patients with primary cutaneous and 
non-cutaneous primary tumor sites. Radiation-associated AS is known to express several angiogenic 
biomarkers (i.e. VEGF) supporting the rationale for angiogenesis inhibitors in patients with these 
tumors.(8) However, no significant difference in response rate was observed between radiation-
associated and non-radiation-associated AS, but the number of patients is in fact too small to draw 
firm conclusions.  
 
HE has a spectrum of behavior from indolent to very aggressive. Overexpression of vascular growth 
factor receptors (VEGF, VEGFR2, and VEGFR3) has been observed in pulmonary HE samples.(22) 
Given its vascular origin, angiogenesis inhibition may be a reasonable therapeutic approach for the 
management of this subtype. Interferon-2, which has some anti-angiogenic activity, has been reported 
to result in responses in some case reports.(23) In the trial by Agulnik et al. the efficacy of 
bevacizumab was assessed in HE and AS. Seven patients with HE were included; two had a partial 
response and four had stable disease.(9) A Phase II trial of sorafenib by the French Sarcoma Group 
included 15 patients with HE; two patients had a partial response and five SD.(24) Our results are 
consistent with the French Sarcoma Group trial, and demonstrate that pazopanib can result in 
RECIST responses in some patients with HE. Additionally, our survival data are consistent with the 
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reported mean survival of approximately 4.6 years including a broad range from 6 months to 24 
years.(25) However, all of these observations are limited by the small patient numbers due to the rarity 
of this disease. 
 
There are few published data regarding systemic therapy in IS, although patients are often treated 
with anthracyclines and ifosfamide.(26) To our knowledge no data of antiangiogenic therapy is 
available in this subtype. In view of both patients achieving a partial response to pazopanib further 
evaluation is warranted in this subtype.  
 
Our study is limited by its retrospective nature and small sample size. However, to our knowledge, this 
report represents the largest published series of patients with advanced vascular sarcomas treated 
with pazopanib. Our study suggests that pazopanib has activity in AS, but the responses observed in 
patients with HE and IS warrant further investigation. Investigating potential predictive markers on a 
molecular level for suggested differences in treatment sensitivity between AS, HE or IS, respectively, 
or between pazopanib responders and non-reponders in the AS cohort would be of major interest. 
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Tables and figures 
Table 1: Patient and tumor characteristics of vascular sarcomas 
 
 Angiosarcoma 
 
N=40 
N (%) 
Epithelioid 
Hemangioendothelioma 
N=10 
N (%) 
Intimal sarcoma 
 
N=2 
N (%) 
Median age (years) 62.4 yrs 47.2 yrs 67.2 yrs 
Gender 
   Female 
   Male 
 
15 (37.5%) 
20 (62.5%) 
 
4 (40%) 
6 (60%) 
 
1 (50%) 
1 (50%) 
Disease stage 
   Locally advanced 
   Metastatic 
 
8 (20%) 
32 (80%) 
 
2 (20%) 
8 (80%) 
 
1 (50%) 
1 (50%) 
Site of primary tumor 
   Breast 
   Scalp/Head 
   Abdomen 
   Thorax 
   Extremity  
 
15 (37.5%) 
6 (15%) 
8 (20%) 
7 (17.5%) 
4 (10%) 
 
0 (0%) 
1 (10%) 
4 (40%) 
4 (40%) 
1 (10%) 
 
0 (0%) 
0 (0%) 
0 (0%) 
1 (50%) 
1(50%) 
Localization 
   Skin 
   Non-skin 
   unknown 
 
15 (37.5%) 
24 (60%) 
1    (2.5%) 
 
0 (0%) 
10 (100%) 
0 (0%) 
 
0 (0%) 
2 (100%) 
0 (0%) 
Radiation-induced 
   Yes 
   No  
 
14 (35%) 
26 (65%) 
 
0 (0%) 
10 (100%) 
 
0 (0%) 
2 (100%) 
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Table 2: Best response to pazopanib 
 
Angiosarcoma 
(N=40) 
Epithelioid 
Hemangioendothelioma 
(N=10) 
Intimal 
sarcoma 
(N=2) 
Total 
(N=52) 
 N (%) N (%) N (%) N (%) 
Best Response                                                                                                                                                                                                         
 Complete Response                   0 (0.0)                                                                                          1 (10.0)                                       0 (0.0) 1 (1.9)                                                           
 Partial Response                    8 (20.0)                                                              1 (10.0)                                                                  2 (100.0)                                   11 (21.2)                                                                                      
 Stable Disease                      7 (17.5)                                                                                         4 (40.0)                                         0 (0.0)                                     11 (21.2)                                                      
 Progressive Disease                23 (57.5)                                                                                         3 (30.0)                                                                   0 (0.0)                                     26 (50.0)                                       
 Unknown                            2 (5.0)                                                                                          1 (10.0)                                       0 (0.0)                                   3 (5.8)
 
Table 3: Response rate (CR and PR) according to RECIST 1.1. for angiosarcoma 
patients 
 
Patients Response 
rate 
 N N (%) 
Localization of first tumor                                                                                                          
 Skin                15 4 (26.7%) 
 Non-skin                 33 8 (24.2%) 
 Missing                 1 0 (0.0%) 
Pazopanib given post-Radiotherapy                    
 Yes              15 4 (26.7%) 
 No 37 8 (23.5%) 
Total 49 12 (24.5%) 
 
 
Table 4: Treatment details before and after pazopanib 
 
Angiosarcoma 
(N=40) 
Epithelioid 
Hemangioendothelioma 
(N=10) 
Intimal 
sarcoma 
(N=2) 
Total 
(N=52) 
 N (%) N (%) N (%) N (%) 
Number of previous treatment lines                                                                                                                                                                                                                                                 
 0                            4 (10.0)                                                                                           1 (10.0)                                      0 (0.0)                                                                            5 (9.6)         
 1                           14 (35.0)                                                                                         2 (20.0)                                     2 (100.0)                                                                                       18 (34.6)
 2                           12 (30.0)                                                                                         5 (50.0)                 0 (0.0)                                                                                     17 (32.7)                        
 >2                            10 (25)                                                                                         2 (20.0)                                      0 (0.0)                                         12 (23.1)                                                            
Number of treatment lines after 
pazopanib                (N=36) 
 
(N=5) 
 
(N=2) 
 
(N=43) 
 N (%) N (%) N (%) N (%) 
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Angiosarcoma 
(N=40) 
Epithelioid 
Hemangioendothelioma 
(N=10) 
Intimal 
sarcoma 
(N=2) 
Total 
(N=52) 
 N (%) N (%) N (%) N (%) 
 0                           18 (50.0)                                                                                         3 (60.0)                                     0 (0.0)                                                                                     21 (48.8)                        
 1                           15 (41.7)                                                                                         2 (40.0)                                     1 (50.0)                                          18 (41.9)                                                                      
 2                            3 (8.3)                                                                                          0 (0.0)                                              1 (50.0)                              4 (9.3)                                                           
 
 
 
Figure 1: PFS in angiosarcoma and epithelioid hemangioendothelioma subgroup 
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Appendix:  
Table 5: Systemic treatments given before and after pazopanib 
 
Patients received previous 
line treatment agents 
(N=46) 
Patients received further 
line treatment agents 
(N=38) 
 
Yes 
N (%) 
Yes 
N (%) 
Paclitaxel                 25 (54.3)                                                                                         7 (18.4) 
Doxorubicin   20 (43.5)                                                                                         2 (5.3) 
Docetaxel                  11 (23.9)                                                                                         2 (5.3) 
Gemcitabine                 11 (23.9)                                                                                         8 (21.1) 
Ifosfamide                  8 (17.4)                                                                                         1 (2.6)
Epirubicin                  7 (15.2)                                                                                         0
Dacarbazine   3 (6.5)                                                                                                                      1 (2.6) 
Brentuximab   2 (4.3)                                                                                          0
Trabectedin   2 (4.3)                                                                                          1 (2.6) 
Alpha interferon   1 (2.2)                                                                                                                      0
Carboplatin                1 (2.2)                                                                                          0
Cyclophosphamide   1 (2.2)                                                                                          2 (5.3) 
Lenalidomide                 1 (2.2)                                                                                                                      0
Melphalan    1 (2.2)                                                                                                                      0
Vinorelbine    1 (2.2)                                                                                          0
Thalidomide    1 (2.2)                                                                                                                      0
Cisplatin 0 1 (2.6) 
Etoposide 0 1 (2.6) 
Pembrolizumab 0 1 (2.6) 
Trofosfamide 0 1 (2.6) 
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